Le Lézard
Classified in: Health
Subject: SVY

European Prostate Cancer Market Outlook to 2026


DUBLIN, July 13, 2018 /PRNewswire/ --

The "Europe Prostate Cancer Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The research provides insights into Prostate Cancer epidemiology, Prostate Cancer diagnosed patients, and Prostate Cancer treatment rate for EU5 countries. The research measures key indicators including prevalence of Prostate Cancer derived from epidemiological analysis, patients diagnosed with Prostate Cancer, and patients treated with a drug therapy.

The research study helps executives estimate Prostate Cancer market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The research provides estimates and forecasts of Prostate Cancer prevalence, Prostate Cancer diagnosis rate, and Prostate Cancer treatment rate for the period 2017-2026. The information is presented by EU5 countries including Germany, France, Spain, Italy, and UK.


Key Topics Covered




1. Prostate Cancer: Disease Definition



2. Prostate Cancer Patient Flow in Europe


2A. Prostate Cancer Prevalence in Europe


2B. Prostate Cancer Diagnosed Patients in Europe


2C. Prostate Cancer Treated Patients in Europe



3. Prostate Cancer Patient Flow in Germany


3A. Prostate Cancer Prevalence in Germany


3B. Prostate Cancer Diagnosed Patients in Germany


3C. Prostate Cancer Treated Patients in Germany



4. Prostate Cancer Patient Flow in France


4A. Prostate Cancer Prevalence in France


4B. Prostate Cancer Diagnosed Patients in France


4C. Prostate Cancer Treated Patients in France



5. Prostate Cancer Patient Flow in Spain


5A. Prostate Cancer Prevalence in Spain


5B. Prostate Cancer Diagnosed Patients in Spain


5C. Prostate Cancer Treated Patients in Spain



6. Prostate Cancer Patient Flow in Italy


6A. Prostate Cancer Prevalence in Italy


6B. Prostate Cancer Diagnosed Patients in Italy


6C. Prostate Cancer Treated Patients in Italy



7. Prostate Cancer Patient Flow in UK


7A. Prostate Cancer Prevalence in UK


7B. Prostate Cancer Diagnosed Patients in UK


7C. Prostate Cancer Treated Patients in UK



8. Research Methodology



For more information about this report visit

https://www.researchandmarkets.com/research/h2p47r/european_prostate?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



SOURCE Research and Markets


These press releases may also interest you

at 18:27
ANDREOZZI + FOOTE CLIENT COMES FORWARD TO SEEK JUSTICE AGAINST RAMON GARCIA
Andreozzi + Foote is deeply troubled by revelations of sexual abuse perpetrated by Ramon Garcia against patients at Carbon Health Urgent Care in Jenkintown and possibly other locations. Our client, Jane Doe, bravely stepped forward to share her...

at 18:14
SARC LAUNCHES GLOBAL SARCOMA CENTERS REGISTRY SUPPORTING PATIENT AND CLINICIAN ACCESS TO PROGRAMS EXPERT IN THE DIAGNOSIS AND TREATMENT OF SARCOMA (RARE AND ULTRARARE CANCER TYPES COMPRISING 15-20% OF CHILDHOOD CANCERS AND 1% OF ADULT CANCERS)
SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce the launch of the Sarcoma Centers Registry https://sarctrials.org/sarcoma-centers/, a comprehensive, global resource facilitating...

at 18:08
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced with great respect and sorrow the unexpected passing last night of...

at 18:02
Indigenous Services Canada announces 2024 recipients of Award of Excellence in Nursing
It takes a unique, special kind of dedication to become a nurse. For the nurses in First Nations and Inuit communities, it takes strength, resiliency, expertise, and most importantly, heart. It takes an understanding of the complex environment of...

at 17:44
EDWARD C. SWEENEY HONORED AT THE CENTER FOR DISCOVERY'S ANNUAL EVENING OF DISCOVERY GALA
On Tuesday, May 7, 2024, The Center for Discovery® (TCFD, The Center) honored Edward C. Sweeney, TCFD Board Chair, at the 24th annual Evening of Discovery Gala. The Gala was hosted by Mo Rocca, CBS Sunday Morning Correspondent, Humorist, and Creator...

at 17:30
Phanes Therapeutics, Inc. Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an anti-PD-L1 Therapy
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...

More news about Health...


News published on and distributed by: